# China NMPA Inspection - Guangxi Faleiao Biotechnology Co., Ltd. - October 18, 2019

Source: https://www.globalkeysolutions.net/records/china_inspection/guangxi-faleiao-biotechnology-co-ltd/bf5069d1-85a8-4d5c-97a3-1479112b8b65/
Source feed: China

> China NMPA unannounced inspection for Guangxi Faleiao Biotechnology Co., Ltd. published October 18, 2019. The Guangxi Zhuang Autonomous Region Drug Administration conducted unannounced inspections of ten cosmetics manufacturers in October 2019, as part of 

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement of the Results of Unannounced Inspections of Cosmetic Manufacturers in Guangxi Zhuang Autonomous Region (Issue 2, 2019)
- Company Name: Guangxi Faleiao Biotechnology Co., Ltd.
- Publication Date: 2019-10-18
- Product Type: Cosmetics
- Summary: The Guangxi Zhuang Autonomous Region Drug Administration conducted unannounced inspections of ten cosmetics manufacturers in October 2019, as part of its 2019 Cosmetics Supervision Work Plan. These inspections were based on the "Key Points for Cosmetic Production License Inspection" to strengthen supervision and ensure product quality. 

Companies inspected included Guangxi Falao Biotechnology (Oct 9-10), Beihai Haizhenzhu Cosmetics (Oct 9-11), Guangxi Mingou Pharmaceutical (Oct 10), Wuzhou Yingbai Biotechnology (Oct 10-11), Guangxi Shidai Meiren Bioengineering (Oct 10-11), Guangxi Luxianna Biotechnology Development (Oct 8-9), Guangxi Laibin Xiangjiang Biotechnology (Oct 9-10), Guangxi Xiecheng Daily Chemical (Oct 11), Guilin Xingrun Cosmetics (Oct 10), and Guilin Changsheng Pharmaceutical (Oct 9).

All manufacturers were found to have multiple deficiencies. Violations ranged from 4 defects (1 serious, 3 general) at Guilin Xingrun and Guilin Changsheng, to 19 defects (4 serious, 15 general) at Beihai Haizhenzhu Cosmetics. Other companies like Guangxi Falao Biotechnology recorded 10 defects (3 serious, 7 general), Guangxi Mingou Pharmaceutical 12 defects (4 serious, 8 general), and Guangxi Shidai Meiren Bioengineering 17 defects (2 serious, 15 general).

Required actions for all companies include immediate rectification, thorough analysis of problem causes, elimination of potential risks, and ensuring product quality and safety. Companies must submit a rectification report upon completion, with some also requiring re-inspection or review by the administration.

Company: https://www.globalkeysolutions.net/companies/guangxi-faleiao-biotechnology-co-ltd/7d2db5a0-e369-4af8-bcb6-d1cc4e3412e4/